Supplementary Figures_S1-S6 from Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors

Figure S1 shows the dose-dependent inhibition of proliferation of T47D cells with wild type or mutant ERα by antiestrogen compounds. Figure S2 shows that the three antiestrogen compounds (K-07, K-09, K-62) and trans-hydroxytamoxifen suppress binding of the coregulator SRC3 to wild type ER and mutant ERs (Y537S, D538G). Figure S3 shows that antiestrogen compounds suppress the proliferation of MCF7 cells or T47D cells containing half mutant and half wild type ERα. Figure S4 shows that antiestrogen compounds induce ERα down-regulation in MCF7 and T47D cells containing half mutant and half wild type ERα. Figure S5 shows that antiestrogen compounds suppress ERα-regulated gene expressions in MCF7 and T47D cells containing half mutant and half wild type ERα. Figure S6 shows that treatment with antiestrogen compounds does not affect the body weights of mice bearing MCF7 xenograft tumors.